Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials
Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities
AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses
Lund, Sweden, 26 March 2025 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the appointment of experienced immunology drug development specialist Shane Olwill as Chief Development Officer (CDO).
